Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVSEF) Payables (2016 - 2025)

Historic Payables for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to $5.1 billion.

  • Novartis Ag's Payables fell 145.76% to $5.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.1 billion, marking a year-over-year decrease of 145.76%. This contributed to the annual value of $5.1 billion for FY2025, which is 145.76% down from last year.
  • Per Novartis Ag's latest filing, its Payables stood at $5.1 billion for Q4 2025, which was down 145.76% from $4.6 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Payables ranged from a high of $6.5 billion in Q4 2021 and a low of $3.9 billion during Q3 2023
  • Moreover, its 5-year median value for Payables was $4.9 billion (2021), whereas its average is $4.9 billion.
  • In the last 5 years, Novartis Ag's Payables crashed by 2513.82% in 2024 and then skyrocketed by 1145.09% in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's Payables stood at $6.5 billion in 2021, then dropped by 6.87% to $6.0 billion in 2022, then decreased by 7.64% to $5.6 billion in 2023, then fell by 6.05% to $5.2 billion in 2024, then fell by 1.46% to $5.1 billion in 2025.
  • Its last three reported values are $5.1 billion in Q4 2025, $4.6 billion for Q3 2025, and $4.5 billion during Q2 2025.